Avalyn Pharma Inc. (AVLN)
NASDAQ: AVLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AVLN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.26B
- EPS (TTM)
- -$3.96
- Dividend yield
- None
- 52-week range
- 22.24 – 40.17
- Day range
- 27.85 – 29.38
- Volume / Avg
- 214.29K / 352.95K
- Beta
- —
- Shares outstanding
- 44.52M
52-week range
AVLN stock today
Avalyn Pharma (AVLN) closed at $28.40 on Nov 20, down 1.05% (-$0.30), versus the S&P 500's 3.70% decline. Shares are 29.3% below their 52-week high of $40.17, set on Aug 18, 2026 and 27.7% above the 52-week low of $22.24, in the middle of the past year's range. Avalyn Pharma has posted a net loss over the last twelve months (EPS of -$3.96), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Avalyn Pharma
Company profileAvalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. The company provides inhaled formulations of oral medicines directly to the lungs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Lyn Baranowski
- Headquarters
- Boston, MA
- Employees
- 56
- IPO year
- 2026
- Website
- avalynpharma.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$61.00+114.79%
- Strong buy 2
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.67 vs $-0.64
- Surprise
- -4.69%
AVLN news
All AVLN newsAvalyn Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LBRXLB Pharmaceuticals Inc | 38.85 | -2.97% | $1.26B | vs AVLN |
| INVAInnoviva Inc. | 18.41 | 0.00% | $1.31B | vs AVLN |
| MNKDMannKind Corporation | 3.85 | -2.53% | $1.24B | vs AVLN |
| SLNSilence Therapeutics Plc American Depository Share | 19.81 | 0.00% | $1.23B | vs AVLN |
| GENBGenerate Biomedicines Inc. | 9.54 | -8.00% | $1.23B | vs AVLN |
| OCULOcular Therapeutix Inc. | 5.57 | -4.95% | $1.23B | vs AVLN |
| NUVBNuvation Bio Inc. Class A | 3.80 | -0.26% | $1.34B | vs AVLN |
| MLYSMineralys Therapeutics Inc. | 13.66 | -3.53% | $1.21B | vs AVLN |
Indexes, lists and sector
Avalyn Pharma stock FAQ
What is Avalyn Pharma's stock price today?
AVLN last traded at $28.40 as of Nov 20, 4:00 PM EST, down 1.05% on the day. Prices are delayed at least 15 minutes.
Who is Avalyn Pharma's CEO?
Ms. Lyn Baranowski is the chief executive officer of Avalyn Pharma Inc., which has about 56 employees.
What is the AVLN 52-week high?
The 52-week high for AVLN is $40.17 and the 52-week low is $22.24. The stock is currently 29.3% below its high.